EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

Romain Aymon iD, Denis Mongin, Romain Guemara, Zubeyir Salis, Johan Askling, Denis Choquette, Catalin Codreanu, Daniela Di Giuseppe, Irini Flouri, Doreen Huschek, Kimme L Hyrich, Florenzo Iannone iD und 17 weitere

Arthritis & Rheumatology · 2025-09 · 77 (9) · 1194-1204

DOI: 10.1002/art.43188 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Arthritis & Rheumatology, online erschienen am 21.05.2025. Verfasst von Romain Aymon und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Janus Kinase Inhibitors, Antirheumatic Agents, Cardiovascular Diseases. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company, Galápagos, AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease‐modifying antirheumatic drugs with other modes of action (bDMARD‐OMA) in a multicountry, real‐world population.

Methods

Patients with RA from 15 registries in the JAK‐pot collaboration were included. MACE incidence was analyzed using two approaches: a within‐registry analysis aggregating country‐specific estimates from registers with >25 incident MACEs through meta‐analysis and an individual‐level data combined analysis. We used adjusted linear mixed Poisson regression to obtain incidence rate ratios (IRRs) of MACEs between treatment groups, accounting for multiple treatment courses.

Results

The study included 73,008 treatment courses (16,417 JAKi, 35,373 TNFi, and 21,218 bDMARD‐OMA) and 828 incident MACEs among 51,233 patients. Median follow‐up time was 1.3 years, with most of the follow‐up concentrated in the first two years of treatment. Incidence rates were 7.0, 7.6, and 11.8 per 1,000 person‐years for JAKi, TNFi, and bDMARD‐OMA, respectively. Compared to TNFi, JAKi (within‐registry adjusted IRR 0.89, 95% confidence interval [CI] 0.63–1.25) had similar incidence rates of MACEs and bDMARD‐OMA had higher rates (within‐registry adjusted IRR 1.35, 95% CI 1.10–1.66). Combined analysis showed similar results.

Conclusion

Observational data from the JAK‐pot collaboration show no evidence of an increase in cardiovascular events during the first two years of use with JAKi compared to TNFi in the general RA population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidJanus Kinase InhibitorsAntirheumatic AgentsCardiovascular DiseasesBiological ProductsHumansRegistriesFemaleMaleIncidenceMiddle AgedAgedTumor Necrosis Factor InhibitorsAdult

Substanzen

Janus Kinase InhibitorsAntirheumatic AgentsTumor Necrosis Factor InhibitorsBiological Products

Autor:innen und Institutionen

  • Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland.
  • University of Montpellier and Physiology and Experimental Medicine of the Heart and Muscles, Montpellier, France.
  • Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Centre Hospitalier de l'Université de Montréal, Institut de Recherche en Rhumatologie, Montréal, Québec, Canada.
  • University of Medicine, Center of Rheumatic Diseases, Bucharest, Romania.
  • Rheumatology and Clinical Immunology, University Hospital of Heraklion, Crete, Greece.

ORCID-Profile: Romain Aymon, Florenzo Iannone, Tore K Kvien, Karel Pavelka, Sella A Provan, Lianne Kearsley-Fleet

Förderung

  • Eli Lilly and Company
  • Galápagos
  • AbbVie
  • Pfizer

Zitieren

APA

Aymon, R., Mongin, D., Guemara, R., Salis, Z., Askling, J., Choquette, D., Codreanu, C., Di Giuseppe, D., Flouri, I., Huschek, D., Hyrich, K. L., Iannone, F., Kvien, T. K., Leeb, B. F., Nordström, D., Otero-Varela, L., Pavelka, K., Pombo-Suarez, M., Rodrigues, A., …, & Lauper, K. (2025). Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries. Arthritis & Rheumatology, 77(9), 1194-1204. https://doi.org/10.1002/art.43188

Vancouver

Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D, et al. Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries. Arthritis & Rheumatology. 2025;77(9):1194-1204. doi:10.1002/art.43188

BibTeX
@article{Aymon2025,
  author = {Aymon, Romain and Mongin, Denis and Guemara, Romain and Salis, Zubeyir and Askling, Johan and Choquette, Denis and Codreanu, Catalin and Di Giuseppe, Daniela and Flouri, Irini and Huschek, Doreen and Hyrich, Kimme L and Iannone, Florenzo and Kvien, Tore K and Leeb, Burkhard F and Nordström, Dan and Otero-Varela, Lucia and Pavelka, Karel and Pombo-Suarez, Manuel and Rodrigues, Ana and Rotar, Ziga and Sidiropoulos, Prodromos and Provan, Sella A and Strangfeld, Anja and Nina, Trokovic and Zavada, Jakub and Kearsley-Fleet, Lianne and Courvoisier, Delphine S and Finckh, Axel and Lauper, Kim},
  title = {Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  volume = {77},
  number = {9},
  pages = {1194--1204},
  doi = {10.1002/art.43188}
}
Kostenlos starten →